- Home
- UNCY
as 05-30-2025 4:00pm EST
Unicycive Therapeutics Inc is a biotechnology company dedicated to developing treatments for certain medical conditions. It is focusing on kidney diseases. The company's manufactures drug, Renazorb, is a novel phosphate-binding agent being developed for the treatment of hyperphosphatemia. Unicycive's other drug, UNI-494, is a new chemical entity with the issued composition of matter patent protection in late preclinical development for the treatment of acute kidney injury. Company's pipeline comprised of two product candidates: Oxylanthanum Carbonate and UNI-494.
| Founded: | 2016 | Country: | United States |
| Employees: | N/A | City: | LOS ALTOS |
| Market Cap: | 78.1M | IPO Year: | 2021 |
| Target Price: | $6.38 | AVG Volume (30 days): | 889.6K |
| Analyst Decision: | Strong Buy | Number of Analysts: | 4 |
| Dividend Yield: | N/A | Dividend Payout Frequency: | N/A |
| EPS: | -0.26 | EPS Growth: | N/A |
| 52 Week Low/High: | $0.20 - $0.96 | Next Earning Date: | 05-14-2025 |
| Revenue: | N/A | Revenue Growth: | N/A |
| Revenue Growth (this year): | N/A | Revenue Growth (next year): | 1422.24% |
Latest Unicycive Therapeutics Inc. News
UNCY Breaking Stock News: Dive into UNCY Ticker-Specific Updates for Smart Investing
GlobeNewswire
10 days ago
Unicycive Therapeutics to Present at Upcoming Investor Conferences
GlobeNewswire
11 days ago
Unicycive Therapeutics Announces Time Change for 2025 Annual Meeting of Stockholders
GlobeNewswire
18 days ago
Unicycive Therapeutics Announces First Quarter 2025 Financial Results and Provides Business Update
Simply Wall St.
25 days ago
Analysts Expect Breakeven For Unicycive Therapeutics, Inc. (NASDAQ:UNCY) Before Long
MT Newswires
a month ago
Guggenheim Initiates Unicycive Therapeutics at Buy With $6 Price Target
GlobeNewswire
2 months ago
Unicycive Presents New Patient-Level Data Underscoring Challenges Faced with Current Phosphate Binders and Highlighting the Potential of Oxylanthanum Carbonate to Address Barriers to Adherence for Patients with Hyperphosphatemia on Dialysis
GlobeNewswire
2 months ago
Unicycive Therapeutics to Present at the 24th Annual Needham Virtual Healthcare Conference
GlobeNewswire
2 months ago
Unicycive Therapeutics Announces Full Year 2024 Financial Results and Provides Business Update
Compare UNCY vs Leading Stocks
Share on Social Networks:
Disclaimer
The information presented on this page, "UNCY Unicycive Therapeutics Inc. - Stocks Price | History | Analysis", including historical data, forecasts, news, insider information, and predictions, is provided for educational purposes only. It should not be considered as financial advice or a recommendation to buy or sell any securities. Decisions regarding investments should be made only after careful consideration and consultation with a qualified financial advisor. We do not endorse or guarantee the accuracy or reliability of the information provided, and we disclaim any liability for financial losses incurred as a result of decisions made based on the information presented.